regulatory
confidence high
sentiment positive
materiality 0.55
Inhibikase regains Nasdaq minimum bid price compliance
Inhibikase Therapeutics, Inc.
- Received Nasdaq notice on July 17, 2023 confirming compliance with Listing Rule 5550(a)(2).
- Closing bid price was at or above $1.00 for 10 consecutive business days ended July 14, 2023.
- The matter is closed; no further action required from the company.